Complement activation in the central nervous system following blood- brain barrier damage in man

Annals of Neurology

Volumn 40, Issue 4, 1996, Pages 587-596

  Lindsberg, Perttu J ^a   Öhman, Juha ^a   Lehto, Timo ^a   Karjalainen Lindsberg, Marja Liisa ^a   Paetau, Anders ^a   Wuorimaa, Tomi ^a   Carpén, Olli ^a   Kaste, Markku ^a   Meri, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CELL INFILTRATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUTROPHIL; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE;

ADULT; ANEURYSM, RUPTURED; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; BLOOD-BRAIN BARRIER; BRAIN; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; EDETIC ACID; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUTROPHILS; NIMODIPINE; SUBARACHNOID HEMORRHAGE; TOMOGRAPHY, X-RAY COMPUTED; VASODILATOR AGENTS;

EID: 0029910943     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400408     Document Type: Article

References (30)

1. Müller-Eberhard HJ. The membrane attack complex of complement. Annu Rev Immunol 1986;4:503-528
2. Brooks BR, Hirsch RL, Coyle PK. Cellular and humoral immune responses in human cerebrospinal fluid. In: Wood JH, ed. Neurobiology of cerebrospinal fluid. New York: Plenum, 1983:300-301
3. Silverberg DH, Manning MC, Schreiber AD. Tissue culture demyelination by normal human serum. Ann Neurol 1984;15: 575-580
4. Scolding NJ, Morgan BP, Houston A, et al. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. J Neurol Sci 1989;89:289-300
5. Wren DR, Noble M. Oligodendrocytes and oligodendrocyte/ type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in the absence of antibody. Proc Natl Acad Sci USA 1989;86:9025-9029
6. Cyong J-C, Witkin SS, Reiger B, et al. Antibody-independent complement activation by myelin via the classical complement pathway. J Exp Med 1982;155:587-598
7. Vanguri P, Koski CL, Silverman B, et al. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci USA 1982;79:3290-3294
8. Morgan BP. Complement. Clinical aspects and relevance to disease. San Diego: Academic Press, 1990:1-185
9. Schäfer H, Mathey D, Hugo F, et al. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 1986;137:1945-1949
10. Rus HG, Niculescu F, Vlaicu R. Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis. Immunol Lett 1987;16:15-20
11. Crawford MH, Grover FL, Kolb WP, et al. Complement and neutrophil activation in the pathogenesis of ischemie myocardial injury. Circulation 1988;78:1449-1458
12. Väkevä A, Laurila P, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 1992;67:608-616
13. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-151
14. Smith EF III, Griswold DE, Egan JW, et al. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Eur J Pharmacol 1993;236:477-481
15. Kalli KR, Hsu P, Fearon DT. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994;15:417-431
16. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994;15:369-396
17. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurasurgery 1980;6:1-9
18. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968:28:14-20
19. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975:1:480-484
20. Tourtellotte WW, Shorr RJ. Cerebrospinal fluid. In: Youmans JR, ed. Neurological surgery. Philadelphia: WB Saunders, 1990:335-343
21. Compston DAS, Morgan BP, Campbell AK, et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316
22. Sanders ME, Koski CL, Robbins D, et al. Activated terminal complement in CSF in Guillain-Barre syndrome and multiple sclerosis. J Immunol 1986;136:4456-4459
23. Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg 1989;71:741-746
24. Fishman RA. Cerebrospinal fluid in cerebrovascular disorders. In: Barnett HJM, ed. Stroke: Pathophysiology, diagnosis and management. New York: Churchill Livingstone, 1992:103-110
25. Peterson JW, Kwun B-D, Teramura A, et al. Immunological reaction against the aging human subarachnoid erythrocyte. J Neurosurg 1989;71:718-726
26. Osaka K, Handa H, Okamoto S. Subarachnoid erythrocytes and their contribution to cerebral vasospasm. In: Wood JH, ed. Neurobiology of cerebrospinal fluid. New York: Plenum, 1980:313-323
27. Takenaka K, Kassell NF, Foley PL, et al. Oxyhemoglobin-induced cytotoxicity and arachidonic acid release in cultured bovine endothelial cells. Stroke 1993;24:839-846
28. Kajita T, Hugli TE. C5a-induced neutrophilia. A primary humoral mechanism for recruitment of neutrophils. Am J Pathol 1990;137:467-477
29. Kohaneck PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992:23:1367-1379
30. Jackson IJ. Aseptic hemogenic meningitis. Arch Neural Psychiatry 1949:62:572-589